Autonomic Drugs in Pharmacology
Learning Objectives
By the end of this page, you should be able to:
- Explain how the sympathetic and parasympathetic divisions of the autonomic nervous system (ANS) produce opposite physiological effects.
- Classify autonomic drugs as sympathomimetics, sympatholytics, parasympathomimetics, or parasympatholytics, and match each class to its receptor target.
- List the major adrenergic (α1, α2, β1, β2, β3) and cholinergic (muscarinic M1-M3, nicotinic Nn/Nm) receptor subtypes with their tissue location and effect.
- Recall high-yield drug examples for each class, including their clinical indications and dose-limiting toxicities.
- Recognize the cholinergic and anticholinergic toxidromes and connect them to receptor pharmacology.
- Predict the physiological consequence of blocking or stimulating a given receptor subtype in a clinical vignette.
Quick Answer
Autonomic drugs act on the receptors of the sympathetic and parasympathetic nervous systems to speed up or slow down involuntary body functions — heart rate, blood pressure, airway diameter, pupil size, gut motility, and glandular secretion. They matter because nearly every organ system has autonomic input, so these drugs are used everywhere in medicine: epinephrine for anaphylaxis, beta-blockers for hypertension, atropine for bradycardia, and anticholinesterases for myasthenia gravis. The key to mastering this topic is not memorizing drug lists — it is knowing which receptor a drug hits and what that receptor normally does, because the effect follows logically from the receptor.
Overview: How the Autonomic Nervous System Works
The ANS controls functions you don't consciously direct — heart rate, digestion, pupil diameter, sweating, bladder tone. It has two main efferent divisions that usually oppose each other, plus the semi-independent enteric system:
- Sympathetic ("fight or flight") — activated by stress; increases heart rate and contractility, dilates bronchioles and pupils, shunts blood to muscle, and inhibits digestion.
- Parasympathetic ("rest and digest") — activated at rest; slows heart rate, constricts pupils, stimulates salivation, digestion, and bladder emptying.
- Enteric nervous system — a semi-autonomous network in the gut wall that coordinates peristalsis and secretion, modulated by sympathetic and parasympathetic input but capable of local reflexes on its own.
Every autonomic drug works by either mimicking or blocking one of two neurotransmitters: norepinephrine/epinephrine (sympathetic) or acetylcholine (parasympathetic and all autonomic ganglia). Once you know which transmitter and which receptor subtype a drug affects, you can predict its effect without memorizing it.
Classification of Autonomic Drugs
1. Sympathomimetics (Adrenergic Agonists)
Definition: Drugs that stimulate adrenergic receptors, reproducing the effects of the sympathetic nervous system.
Explanation: They act directly (binding α or β receptors themselves, e.g., epinephrine) or indirectly (increasing endogenous norepinephrine release or blocking its reuptake, e.g., amphetamine, cocaine). The physiological effect depends entirely on which receptor subtype predominates:
- α1 (vascular smooth muscle, radial iris muscle, bladder sphincter) → vasoconstriction, mydriasis, urinary retention.
- α2 (presynaptic nerve terminals, CNS) → inhibits further NE release; central α2 agonists (clonidine) lower blood pressure and sedate.
- β1 (heart, kidney JG cells) → increased heart rate, contractility, and renin release.
- β2 (bronchial, vascular, uterine smooth muscle) → bronchodilation, vasodilation, uterine relaxation (tocolysis).
- β3 (adipose, detrusor muscle) → lipolysis; mirabegron uses this for overactive bladder.
Example: Phenylephrine, a pure α1 agonist, is dripped into the nose as a decongestant because it constricts nasal blood vessels — no cardiac or bronchial effect because it doesn't touch β receptors.
Real-World Example: Epinephrine in an EpiPen hits α1, β1, and β2 simultaneously during anaphylaxis — it reverses vasodilation and hypotension (α1), boosts a failing heart (β1), and opens closing airways (β2). That's why epinephrine, not an antihistamine, is first-line for anaphylaxis.
Why It Matters: Choosing the right sympathomimetic for the right receptor profile is a daily clinical decision — a cardiologist wants β1 selectivity (dobutamine) to support a failing heart without triggering tachyarrhythmia, while a pulmonologist wants β2 selectivity (albuterol) to avoid unwanted cardiac stimulation.
Common Misunderstanding: Students assume "adrenergic agonist" always raises blood pressure. In reality, isolated β2 agonists (like albuterol) can cause mild hypotension and tremor, and central α2 agonists (clonidine) actively lower blood pressure.
Indications: Anaphylaxis, cardiac arrest/shock, asthma/COPD, nasal congestion, hypotension.
Examples: Epinephrine (anaphylaxis, cardiac arrest — α1/β1/β2), Albuterol (asthma — β2 selective), Dobutamine (cardiogenic shock — β1 selective), Phenylephrine (nasal decongestant, hypotension — α1 selective), Clonidine (hypertension, opioid withdrawal — central α2).
2. Sympatholytics (Adrenergic Antagonists)
Definition: Drugs that block adrenergic receptors, reducing sympathetic tone.
Explanation: Beta-blockers reduce heart rate, contractility, and renin release by blocking β1 (cardioselective agents like metoprolol and atenolol) or both β1/β2 (non-selective agents like propranolol). Alpha-blockers (prazosin, doxazosin — α1 selective; phentolamine — non-selective) cause vasodilation and lower peripheral resistance.
Example: Propranolol blunts the tachycardia and tremor of a panic attack because it blocks the peripheral β1/β2 effects of circulating catecholamines, even though it doesn't touch the underlying anxiety in the brain.
Real-World Example: A patient with benign prostatic hyperplasia is given tamsulosin, an α1A-selective blocker, to relax the prostate and bladder-neck smooth muscle and improve urine flow — chosen over a non-selective α1 blocker specifically to minimize orthostatic hypotension.
Why It Matters: Non-selective beta-blockers are relatively contraindicated in asthmatics because blocking β2 receptors in the bronchi can precipitate bronchospasm — a classic exam trap.
Common Misunderstanding: Students think all beta-blockers are interchangeable. Cardioselectivity (β1 vs non-selective) determines whether a drug is safe in reactive airway disease, and intrinsic sympathomimetic activity (e.g., pindolol) changes the resting heart-rate effect.
Indications: Hypertension, angina, arrhythmias, heart failure (specific agents), performance anxiety, BPH (α1-blockers), pheochromocytoma (pre-op α-blockade with phenoxybenzamine before β-blockade).
Examples: Propranolol (non-selective beta-blocker), Metoprolol (β1-selective), Prazosin (α1 antagonist — hypertension, PTSD nightmares), Phenoxybenzamine (irreversible non-selective α-blocker, pheochromocytoma prep).
3. Parasympathomimetics (Cholinergic Agonists / Cholinomimetics)
Definition: Drugs that stimulate cholinergic receptors, reproducing parasympathetic effects.
Explanation: Direct agonists (pilocarpine, bethanechol) bind muscarinic receptors directly. Indirect agonists — acetylcholinesterase inhibitors (neostigmine, physostigmine, donepezil, organophosphates) — block the enzyme that degrades acetylcholine, so endogenous ACh accumulates at both muscarinic and nicotinic sites.
Example: Bethanechol is used post-operatively for urinary retention because it directly activates M3 receptors on the detrusor muscle, causing bladder contraction.
Real-World Example: Neostigmine reverses non-depolarizing neuromuscular blockade at the end of surgery by boosting ACh at the nicotinic neuromuscular junction — but it must be co-administered with glycopyrrolate (an antimuscarinic) to block the unwanted muscarinic side effects (bradycardia, salivation, bronchospasm) it would otherwise cause.
Why It Matters: This class illustrates a core pharmacology principle — the same neurotransmitter (ACh) acts on two structurally different receptor families (muscarinic G-protein-coupled and nicotinic ligand-gated ion channel), so a single drug's effect depends on which family it reaches and at what dose.
Common Misunderstanding: Students conflate "cholinergic" with "only slows the heart." Cholinergic stimulation also constricts the pupil (miosis), increases GI/bladder motility, and increases secretions — effects that are often tested via the organophosphate poisoning vignette.
Indications: Glaucoma (open-angle), myasthenia gravis, post-op/neurogenic urinary retention, reversal of neuromuscular blockade, Alzheimer's disease (centrally acting AChE inhibitors).
Examples: Pilocarpine (glaucoma, direct M agonist), Bethanechol (urinary retention, direct M agonist), Neostigmine (myasthenia gravis, indirect — does not cross blood-brain barrier), Physostigmine (antidote for anticholinergic toxicity — crosses BBB), Donepezil (Alzheimer's disease).
4. Parasympatholytics (Anticholinergics / Antimuscarinics)
Definition: Drugs that block muscarinic receptors, reducing parasympathetic tone.
Explanation: By blocking M receptors, these drugs dry secretions, dilate the pupil, relax smooth muscle, and speed the heart. Most clinically used agents are antimuscarinic rather than true ganglionic/nicotinic blockers.
Example: Atropine given during a code for symptomatic bradycardia blocks the vagal M2 receptors on the SA node, unopposing the sympathetic drive and speeding the heart rate.
Real-World Example: Scopolamine patches are used for motion sickness because they cross into the CNS and block the vestibular muscarinic pathways that trigger nausea — a good example of how lipophilicity determines whether an anticholinergic acts centrally or only peripherally.
Why It Matters: Recognizing the anticholinergic toxidrome quickly is a patient-safety skill — an elderly patient on multiple anticholinergic medications (antihistamines, tricyclics, bladder antimuscarinics) is at real risk of delirium, urinary retention, and heat stroke from impaired sweating.
Common Misunderstanding: Students mix up the cholinergic toxidrome (SLUDGE — salivation, lacrimation, urination, defecation, GI upset, emesis) with the anticholinergic toxidrome, which is nearly the opposite: "dry as a bone, red as a beet, blind as a bat, mad as a hatter, hot as a hare."
Indications: Bradycardia, pre-operative secretion control, motion sickness, overactive bladder, COPD/asthma (bronchodilation via M3 blockade), organophosphate poisoning (antidote).
Examples: Atropine (bradycardia, organophosphate poisoning antidote), Ipratropium (inhaled, COPD/asthma), Scopolamine (motion sickness, crosses BBB), Oxybutynin (overactive bladder), Benztropine (Parkinsonism, drug-induced extrapyramidal symptoms).
5. Ganglionic Blockers
Definition: Drugs that block nicotinic (Nn) receptors at autonomic ganglia, interrupting both sympathetic and parasympathetic outflow simultaneously.
Explanation: Because both divisions pass through nicotinic ganglionic synapses, blocking Nn receptors produces a mixed, often unpredictable picture — whichever division normally dominates a given organ loses its tone (e.g., the gut, normally parasympathetic-dominant, becomes atonic; the vasculature, normally sympathetic-dominant, dilates).
Example: Hexamethonium was historically used for hypertensive emergencies but caused severe orthostatic hypotension, constipation, and blurred vision because it shut down autonomic control everywhere, not just at the target organ.
Why It Matters: This class is largely historical, but it is a favorite exam concept for illustrating "dominant tone" — the idea that ganglionic blockade unmasks whichever division normally controls an organ.
Common Misunderstanding: Students expect ganglionic blockers to have one clean, predictable effect like a selective receptor drug — they don't, and that unpredictability is exactly why they were abandoned in favor of selective agents.
Indications: Historically hypertensive emergencies (obsolete; replaced by selective vasodilators and beta-blockers).
Examples: Hexamethonium, Trimethaphan (historical use in controlled hypotension during surgery).
Clinical Applications by System
| System | Sympathomimetic use | Sympatholytic use | Parasympathomimetic use | Parasympatholytic use |
|---|---|---|---|---|
| Cardiovascular | Cardiac arrest, shock (epinephrine, dobutamine) | Hypertension, angina, arrhythmia (beta-blockers) | Rarely used (some antiarrhythmics) | Bradycardia (atropine) |
| Respiratory | Bronchospasm relief (albuterol) | Avoided in asthma (non-selective beta-blockers) | Not used (would worsen bronchospasm) | Bronchodilation (ipratropium) |
| Ophthalmic | Pupil dilation for exams (phenylephrine) | — | Glaucoma, miosis (pilocarpine) | Mydriasis for exams (tropicamide, atropine) |
| GI/GU | — | — | Urinary retention (bethanechol) | IBS, overactive bladder (oxybutynin, hyoscyamine) |
| Neuromuscular | — | — | Myasthenia gravis, reversal of blockade (neostigmine) | Antidote for cholinergic excess (atropine) |
Key Terms
| Term | Definition |
|---|---|
| Adrenergic receptor | A receptor activated by norepinephrine/epinephrine; subtypes α1, α2, β1, β2, β3 each couple to different G-proteins and produce different effects. |
| Cholinergic receptor | A receptor activated by acetylcholine; divided into muscarinic (GPCR, M1-M5) and nicotinic (ligand-gated ion channel, Nn and Nm) families. |
| Sympathomimetic | A drug that mimics sympathetic nervous system activity by stimulating adrenergic receptors, directly or indirectly. |
| Sympatholytic | A drug that blocks adrenergic receptors, reducing sympathetic effects. |
| Parasympathomimetic (cholinomimetic) | A drug that mimics parasympathetic activity by stimulating cholinergic receptors. |
| Parasympatholytic (antimuscarinic) | A drug that blocks muscarinic receptors, reducing parasympathetic effects. |
| Cholinergic toxidrome (SLUDGE/DUMBELS) | The symptom cluster of cholinergic excess: salivation, lacrimation, urination, defecation, GI cramping, emesis, miosis, bronchorrhea — classic in organophosphate poisoning. |
| Anticholinergic toxidrome | "Dry as a bone, red as a beet, blind as a bat, mad as a hatter, hot as a hare, full as a flask" — dry mouth/skin, flushing, mydriasis/cycloplegia, delirium, hyperthermia, urinary retention. |
| Cardioselectivity | The property of a beta-blocker (e.g., metoprolol, atenolol) preferentially blocking β1 over β2 at low doses, making it safer in reactive airway disease. |
| Dominant tone | The autonomic division that normally controls an organ at rest; ganglionic blockade unmasks loss of whichever tone dominates that organ. |
Common Mistakes
Misconception 1: "All beta-blockers are the same, so any one is safe in asthma." Why it's wrong: Non-selective beta-blockers (propranolol, nadolol) block β2 receptors in bronchial smooth muscle, which can trigger bronchospasm in a patient with reactive airway disease. Correct understanding: Cardioselective agents (metoprolol, atenolol, bisoprolol) are preferred in patients with asthma/COPD, though even these lose selectivity at higher doses.
Misconception 2: "Atropine and epinephrine do the same thing because both speed up the heart." Why it's wrong: They act on completely different receptors — atropine blocks inhibitory muscarinic (M2) input to the SA node, while epinephrine directly stimulates excitatory β1 receptors. The mechanism, potency, and side-effect profile differ substantially. Correct understanding: Atropine "removes the brake" (vagal tone); epinephrine "presses the accelerator" (direct sympathetic stimulation). This distinction matters clinically — atropine is preferred first-line for symptomatic bradycardia, while epinephrine is reserved for cardiac arrest or when atropine fails.
Misconception 3: "Cholinergic and anticholinergic toxidromes are hard to tell apart because both are 'autonomic' poisonings." Why it's wrong: Students often confuse the direction of secretions and skin findings between the two syndromes. Correct understanding: They are near-opposites — cholinergic excess (organophosphates) causes wet, constricted findings (salivation, sweating, miosis, bradycardia), while anticholinergic excess (atropine overdose, antihistamine overdose, TCA overdose) causes dry, dilated findings (dry skin, mydriasis, tachycardia, delirium, hyperthermia).
Comparison and Connections
| Feature | Sympathomimetics | Sympatholytics | Parasympathomimetics | Parasympatholytics |
|---|---|---|---|---|
| Receptor action | Stimulate α/β receptors | Block α/β receptors | Stimulate muscarinic/nicotinic receptors | Block muscarinic receptors |
| Neurotransmitter mimicked/blocked | Norepinephrine/epinephrine | Norepinephrine/epinephrine | Acetylcholine | Acetylcholine |
| Effect on heart rate | Increase (β1) | Decrease (β1 block) | Decrease (M2) | Increase (M2 block) |
| Effect on pupil | Mydriasis (α1) | Minimal | Miosis (M3) | Mydriasis (M3 block) |
| Effect on airway | Bronchodilation (β2) | Bronchoconstriction risk (non-selective β block) | Bronchoconstriction (M3) | Bronchodilation (M3 block) |
| Classic toxidrome | Sympathetic excess: hypertension, tachycardia, mydriasis, diaphoresis | Bradycardia, hypotension, bronchospasm (in susceptible patients) | Cholinergic (SLUDGE/DUMBELS) | Anticholinergic ("dry, red, blind, mad, hot") |
| Prototype drug | Epinephrine | Propranolol | Pilocarpine / Neostigmine | Atropine |
Practice Questions
Recall
-
Name the four adrenergic receptor subtypes discussed and one tissue where each is found. Answer guidance: α1 (vascular smooth muscle, iris dilator, bladder sphincter), α2 (presynaptic terminals), β1 (heart, kidney JG cells), β2 (bronchial/vascular/uterine smooth muscle).
-
What enzyme do acetylcholinesterase inhibitors block, and what accumulates as a result? Answer guidance: They block acetylcholinesterase, so acetylcholine accumulates at both muscarinic and nicotinic synapses.
Understanding
-
Explain why phenylephrine is preferred over epinephrine as a nasal decongestant even though both are sympathomimetics. Answer guidance: Phenylephrine is α1-selective, so it constricts nasal vasculature without epinephrine's added β1 cardiac stimulation and β2 bronchial/vascular effects, reducing systemic side effects.
-
Why must glycopyrrolate or atropine be given alongside neostigmine when reversing neuromuscular blockade? Answer guidance: Neostigmine raises ACh everywhere, including muscarinic sites (bradycardia, secretions, bronchospasm); the antimuscarinic blocks those unwanted muscarinic effects while leaving the desired nicotinic (neuromuscular) reversal intact.
Application
-
A patient with COPD is newly started on propranolol for migraine prophylaxis and develops wheezing. What is happening pharmacologically, and what would you change? Answer guidance: Propranolol is non-selective and blocks β2 receptors in the bronchi, removing bronchodilatory tone and worsening airway resistance; switch to a cardioselective beta-blocker or a non-beta-blocker migraine prophylactic agent.
-
An elderly patient on diphenhydramine (an antihistamine with antimuscarinic activity), oxybutynin, and a tricyclic antidepressant presents with confusion, dry flushed skin, dilated pupils, and a fever. What toxidrome is this, and which receptor class is responsible? Answer guidance: Anticholinergic toxidrome — cumulative antimuscarinic burden from three drugs blocking M receptors; treat by stopping offending agents and, if severe, considering physostigmine (a centrally-penetrant AChE inhibitor).
Analysis
-
Compare and contrast why atropine speeds the heart while a beta-blocker slows it, even though both are called "autonomic drugs." Answer guidance: Atropine blocks inhibitory vagal (M2) tone on the SA node, removing a brake so intrinsic sympathetic/pacemaker activity dominates; beta-blockers directly block the excitatory β1 receptors that drive rate and contractility. One removes inhibition, the other removes stimulation — opposite mechanisms, same organ.
-
A ganglionic blocker and a combination of an alpha-blocker plus a beta-blocker can both theoretically reduce blood pressure. Why are selective alpha/beta blockers preferred clinically over ganglionic blockers today? Answer guidance: Ganglionic blockers shut down all autonomic ganglionic transmission indiscriminately, producing unpredictable effects across every organ system (GI atony, urinary retention, blurred vision, severe orthostasis), whereas selective adrenergic blockers target only the intended receptor system, giving a more predictable and tolerable side-effect profile.
FAQ
Q1: What's the simplest way to remember which receptors do what? Anchor to the "job" of each division: sympathetic revs the body up (β1 heart, β2 airway/vessels, α1 vasoconstriction), parasympathetic calms it down (M2 heart, M3 glands/smooth muscle). Once you know the job, the receptor effect follows logically.
Q2: Why do some drugs affect both muscarinic and nicotinic receptors while others are selective? It depends on structure. Acetylcholinesterase inhibitors raise ACh globally, so they hit every cholinergic synapse (muscarinic and nicotinic) non-selectively. Direct-acting drugs like pilocarpine or bethanechol are synthesized to fit only the muscarinic receptor pocket.
Q3: Is epinephrine a sympathomimetic even though it's a natural hormone? Yes — "sympathomimetic" describes the pharmacological action (mimicking the sympathetic nervous system), not whether the substance is synthetic or endogenous. When given as a drug, epinephrine is classified as a direct-acting sympathomimetic.
Q4: Why is atropine used both to treat bradycardia and as an antidote for organophosphate poisoning? In both cases, atropine blocks excessive muscarinic (M2/M3) activity — whether that excess is coming from normal vagal tone slowing the heart too much, or from an organophosphate flooding every muscarinic synapse with acetylcholine.
Q5: Why don't ganglionic blockers work well as antihypertensives if they block sympathetic outflow to blood vessels? Because they block parasympathetic ganglia too, causing severe side effects (GI paralysis, urinary retention, blurred vision) that outweigh the blood-pressure benefit — which is exactly why selective drugs (beta-blockers, alpha-blockers, ACE inhibitors) replaced them.
Quick Revision
- ANS has two opposing efferent divisions: sympathetic (fight/flight) and parasympathetic (rest/digest), plus the semi-independent enteric system.
- Sympathomimetics stimulate adrenergic receptors: α1 = vasoconstriction/mydriasis, α2 = decreased NE release, β1 = increased HR/contractility, β2 = bronchodilation/vasodilation.
- Sympatholytics block adrenergic receptors — non-selective beta-blockers (propranolol) risk bronchospasm; cardioselective agents (metoprolol) are safer in asthma.
- Parasympathomimetics stimulate cholinergic receptors, either directly (pilocarpine, bethanechol) or indirectly via AChE inhibition (neostigmine, physostigmine).
- Parasympatholytics (atropine, ipratropium, scopolamine) block muscarinic receptors, drying secretions and speeding the heart.
- Ganglionic blockers (hexamethonium) block nicotinic ganglionic receptors and affect both divisions unpredictably — now obsolete.
- Cholinergic toxidrome = SLUDGE/DUMBELS (wet, slow, constricted) — classic in organophosphate poisoning.
- Anticholinergic toxidrome = "dry as a bone, red as a beet, blind as a bat, mad as a hatter, hot as a hare" (dry, fast, dilated).
- Neostigmine reverses neuromuscular blockade but must be paired with an antimuscarinic (glycopyrrolate/atropine) to prevent bradycardia and secretions.
- Physostigmine crosses the blood-brain barrier and is the antidote for severe anticholinergic toxicity; neostigmine does not cross and cannot treat CNS anticholinergic effects.
- Epinephrine's triple receptor action (α1, β1, β2) makes it first-line for anaphylaxis over antihistamines alone.
- Ganglionic blockade "unmasks" the dominant autonomic tone of an organ — a useful concept for predicting unexpected effects.
Related Topics
Prerequisites: Basic neurophysiology of synaptic transmission; general pharmacodynamics (agonist vs antagonist, receptor binding); anatomy of the autonomic nervous system.
Related Topics: Neuromuscular blocking agents and anesthesia pharmacology; cardiovascular pharmacology (antihypertensives, antiarrhythmics); toxicology and toxidrome recognition; ophthalmic pharmacology (glaucoma agents, mydriatics).
Next Topics: CNS pharmacology (neurotransmitters beyond ACh/NE — dopamine, serotonin, GABA); drugs affecting the renin-angiotensin-aldosterone system; pharmacology of the respiratory system (bronchodilators in depth).